Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 3/20 | 0.37 |
| ▸ | CDK2 | P24941 | 3/20 | 0.37 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.37 |
| ▸ | CDK1 | P06493 | 1/20 | 0.37 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.33 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | CCR1 | P32246 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29983687 | 1.00 | CCNA2 (0.37) | CCNA2CDK2CCNA1CDK1CCNB1 | |
| SCHEMBL21582555 | 0.82 | LPAR1 (0.34) | KMT2AKDM4ENOS3NOS2CCR1 | |
| SCHEMBL29813506 | 0.82 | LPAR1 (0.34) | KMT2AKDM4ENOS3NOS2CCR1 | |
| Hydrochloric Acid SCHEMBL30844835 | 0.81 | LPAR1 (0.34) | KDM4ENOS3NOS2CCR1RAB9A | |
| SCHEMBL25009795 | 0.80 | CCNA2 (0.37) | CCNA2CDK2CCNA1CDK1CCNB1 | |
| SCHEMBL29210880 | 0.79 | GRM5 (0.32) | KDM4ENOS3NOS2CCR1RAB9A | |
| SCHEMBL21585395 | 0.79 | KMT2A (0.41) | CCNA2CDK2CCNA1CDK1CCNB1 | |
| SCHEMBL25010693 | 0.79 | MCHR1 (0.43) | CDK2CDK1KDM4EUSP2HPGD | |
| SCHEMBL25010689 | 0.79 | MCHR1 (0.43) | CDK2CDK1KDM4EUSP2HPGD | |
| SCHEMBL30271340 | 0.79 | MCHR1 (0.43) | CDK2CDK1KDM4EUSP2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12539294-B2 | Combination of an azetidine LPA1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases | IDORSIA PHARMACEUTICALS LTD (CH) | 2026-02-03 | — | — | US | disclosed |
| US-12344597-B2 | Alkoxy-substituted pyridinyl derivatives as LPA1 receptor antagonists and their use in the treatment of fibrosis | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-07-01 | — | — | US | disclosed |
| CN-112236424-B | Alkoxy-substituted pyridinyl derivatives | 爱杜西亚药品有限公司 | 2024-03-15 | — | — | CN | disclosed |
| US-20230000846-A1 | COMBINATION OF AN AZETIDINE LPA1 RECEPTOR ANTAGONIST WITH PIRFENIDONE AND/OR NINTEDANIB FOR USE IN THE TREATMENT OF FIBROTIC DISEASES | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-01-05 | — | — | US | disclosed |
| EP-4069227-A1 | COMBINATION OF AN AZETIDINE LPA1 RECEPTOR ANTAGONIST WITH PIRFENIDONE AND/OR NINTEDANIB FOR USE IN THE TREATMENT OF FIBROTIC DISEASES | Idorsia Pharmaceuticals Ltd (CH) | 2022-10-12 | — | — | EP | disclosed |
| CN-114761001-A | Combination of azetidine LPA1 receptor antagonists with anti-fibrotic agents | 爱杜西亚药品有限公司 | 2022-07-15 | — | — | CN | disclosed |
| US-20210246116-A1 | ALKOXY-SUBSTITUTED PYRIDINYL DERIVATIVES AS LPA1 RECEPTOR ANTAGONISTS AND THEIR USE IN THE TREATMENT OF FIBROSIS | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-08-12 | — | — | US | disclosed |
| WO-2021110805-A1 | COMBINATION OF AN AZETIDINE LPA1 RECEPTOR ANTAGONIST WITH PIRFENIDONE AND/OR NINTEDANIB FOR USE IN THE TREATMENT OF FIBROTIC DISEASES | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-06-10 | — | — | WO | disclosed |
| CN-112236424-A | Alkoxy-substituted pyridyl derivatives | 爱杜西亚药品有限公司 | 2021-01-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12344597-B2 | Alkoxy-substituted pyridinyl derivatives as LPA1 receptor antagonists and their use in the treatment of fibrosis | LPAR1, LPAR3, LPAR2 | CCNA2 1693/4885CDK2 1023/4885CCNA1 573/4885 |
| US-12539294-B2 | Combination of an azetidine LPA1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases | LPAR2, LPAR1, LPAR3 | CCNA2 2883/4885CDK2 1581/4885CCNA1 1975/4885 |
| US-20230000846-A1 | COMBINATION OF AN AZETIDINE LPA1 RECEPTOR ANTAGONIST WITH PIRFENIDONE AND/OR NINTEDANIB FOR USE IN THE TREATMENT OF FIBROTIC DISEASES | LPAR1, LPAR2, LPAR3 | CCNA2 2181/4885CDK2 1263/4885CCNA1 810/4885 |
| US-20210246116-A1 | ALKOXY-SUBSTITUTED PYRIDINYL DERIVATIVES AS LPA1 RECEPTOR ANTAGONISTS AND THEIR USE IN THE TREATMENT OF FIBROSIS | LPAR1, LPAR3, LPAR2 | CCNA2 1693/4885CDK2 1023/4885CCNA1 573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.